X0202 SCHEDULE 13G 0002071860 XXXXXXXX LIVE Common Stock, $0.0001 par value 08/17/2026 0001401914 Dare Bioscience, Inc. 23666P200 3655 Nobel Drive Suite 260 San Diego CA 92122 Rule 13d-1(c) Lind Global Fund III LP b DE 1094890 0 1094890 0 1094890 N 5.65 PN (1) The reporting person's ownership consists of (i) 1,094,890 shares of common stock, (ii) 1,094,890 warrants to purchase shares of common stock (the "Series A Warrants"), and (iii) 1,094,890 warrants to purchase shares of common stock (the "Series B Warrants," together with the Series A Warrants, the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 1,094,890 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company. Lind Global Partners III LLC b DE 1094890 0 1094890 0 1094890 N 5.65 OO (1) The reporting person's ownership consists of (i) 1,094,890 shares of common stock, (ii) 1,094,890 Series A Warrants, and (iii) 1,094,890 Series B Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 1,094,890 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company. EASTON JEFF b X1 1094890 0 1094890 0 1094890 N 5.65 IN (1) The reporting person's ownership consists of (i) 1,094,890 shares of common stock, (ii) 1,094,890 Series A Warrants, and (iii) 1,094,890 Series B Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 1,094,890 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company. Dare Bioscience, Inc. 3655 Nobel Drive, Suite 260, San Diego, California, 92122 This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): Lind Global Fund III LP, a Delaware limited partnership; Lind Global Partners III LLC, a Delaware limited liability company; and Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP. Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP. The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022 See Row 4 of cover page for each Reporting Person. Y See Row 9 of cover page for each Reporting Person. See Row 11 of cover page for each Reporting Person. See Row 5 of cover page for each Reporting Person. See Row 6 of cover page for each Reporting Person. See Row 7 of cover page for each Reporting Person. See Row 8 of cover page for each Reporting Person. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 99.1 - Joint Filing Agreement Lind Global Fund III LP Lind Global Partners III LLC, its General Partner 08/28/2026 Lind Global Partners III LLC Lind Global Partners III LLC 08/28/2026 EASTON JEFF Jeff Easton 08/28/2026